Imazapic is a selective herbicide for both the pre- and post-emergent control of some annual and perennial grasses and some broadleaf weeds. Imazapic kills plants by inhibiting the production of branched chain amino acids, which are necessary for protein synthesis and cell growth. It has been useful for weed control in natural areas, particularly in conjunction with the establishment of native warm-season prairie grasses and certain legumes. Imazapic is relatively non-toxic to terrestrial and aquatic mammals, birds, and amphibians. It has a low level of toxicity to birds but is more toxic to aquatic life and honey bees. It has a high potential for bioaccumulation. Imazapic has an average half-life of 120 days in soil. It is may be persistent in soil systems but usually degrades quickly in aquatic systems via photolysis. It has a high aqueous solubility, is volatile and, based on its chemical properties, is moderately mobile and may leach to groundwater.

Nutlins are cis-imidazoline analogs which inhibit the interaction between mdm2 and tumour suppressor p53. Inhibiting the interaction between mdm2 and p53 stabilizes p53, and is thought to selectively induce a growth-inhibiting state called senescence in cancer cells. These compounds are therefore thought to work best on tumors that contain normal or "wild-type" p53. Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis.

Relamorelin (also known as BIM28131 or RM-131) is a synthetic, selective, prokinetic ghrelin analog that was developed for treatment of gastrointestinal motility disorders (such as chronic constipation and diabetic gastroparesis). Relamorelin was shown to relief symptoms such as nausea, fullness, bloating and abdominal pain. It is safe and well-tolerated in healthy individuals, and has no neurological or cardiovascular adverse effects, making this a promising drug with an advantage over other available therapies. A phase III clinical trial comparing the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG) was still ongoing in 2019.

LY3023414, an investigational drug, is a small molecule that that demonstrates activity against PI3K, mTOR, and DNA-PK in tumor cells, thereby inducing cell-cycle effects and inhibiting cancer cell viability. As shown in vitro LY3023414 inhibits the ability of PI3K and mTOR to phosphorylate substrates in the PI3K/mTOR pathway, one of the most frequently mutated pathways in cancer, leading to cancer progression and resistance to existing treatments. Downstream target inhibition by LY3023414 occurs rapidly via an intermittent “on/off” mechanism that may enhance the drug's clinical tolerability, which may in turn allow LY3023414 to overcome some of the toxicities associated with PI3K/mTOR inhibitors and potentially reduce the emergence of feedback mechanisms leading to resistance. The physicochemical and absorption properties of LY3023414 are favorable, as evidenced by the molecule's high solubility across a wide pH range and high oral bioavailability. On the basis of these findings, LY3023414 is currently being evaluated in clinical trials in patients with advanced cancer such as metastatic prostate cancer and non-small cell lung cancer in combination with other chemotherapeutic agents and in endometrial cancer as a monotherapy.

FLORTAUCIPIR is a gamma-carboline derivative. Its 18F radiolabelled form is a highly selective positron emission tomography (PET) tracer targeting paired helical filament (PHF)-tau in the brain. This tracer is studying for clinical assessment in patients with various tauopathies, including Alzheimer's disease.

Glucalox an antacid that was used as a digestive agent. Information about the current use of this compound is not available.

AL 102 (previously known as BMS 986115), was developed as an orally active a gamma-secretase and pan-Notch inhibitor. The drug participated in phase I clinical trials in solid tumor patients. The drug was safe and well-tolerated and stabilized disease for more than six months in 14% of patients, however, Bristol-Myers Squibb terminated the study because of the changes in the business objectives. Ayala, an Israeli biotech company, licensed rights for the development of AL 102 from Bristol-Myers Squibb. In December 2018, Ayala in collaborating with Novartis decided to investigate AL102 for treatment of multiple myeloma. Ayala studied AL102, an inhibitor of the Notch pathway, in blood cancers. It is known that the pathway regulates cell-fate determination during development and maintains adult tissue balance. Cumulative evidence indicates that Notch is overactive in multiple myeloma and participates in its onset and progression.